Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
- 417 Downloads
Nonalcoholic fatty liver disease (NAFLD) is now a frequent cause of consultation for hepatologists and other health care providers. To a significant extent, this is because the metabolic abnormalities associated with obesity and type 2 diabetes mellitus (T2DM) promote liver disease and are more prevalent than ever before. Clinicians must be aware that insulin resistance and hyperglycemia are believed to worsen the natural history of NAFLD, fueling inflammation, hepatocyte injury (ballooning) and fibrosis. End-stage liver disease and hepatocellular carcinoma (HCC) develop more often in this setting. Interventions that reverse insulin resistance and hyperglycemia, may halt or ameliorate the disease process. Therefore, a comprehensive approach is needed for the successful management of these patients that addresses both, the liver-specific and the associated metabolic conditions. This review focuses on the mechanisms by which insulin resistance, and both lipo- and glucotoxicity, are believed to contribute to the development of NAFLD, and on the treatments tested in obese patients with T2DM and NAFLD, as a means to assist practitioners managing these complex patients.
KeywordsFatty liver Nonalcoholic fatty liver disease (NAFLD) Steatosis Nonalcoholic steatohepatitis (NASH) Treatment Type 2 diabetes mellitus Obesity Insulin resistance Hyperglycemia Lipotoxicity Glucotoxicity Pioglitazone, Vitamin E Obeticholic acid Metformin Exenatide Liraglutide
This work was supported by the American Diabetes Association (to K. C.) and a VA Merit Award (1 I01 CX000167-01; to K. C.).
Compliance with Ethics Guidelines
Conflict of Interest
Paola Portillo-Sanchez, Sahzene Yavuz, Fernando Bril and Kenneth Cusi declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.••Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23. Recent guidelines elicited on the management of NAFLD are must-read for clinicians taking care of these patients. PubMedGoogle Scholar
- 3.••Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–25. e716. A comprehensive review on the mechanisms by which obesity predisoses to NAFLD, including how NAFLD relates to dyslipidemia, T2DM and cardiovascular disease. The review also elaborates on treatments, in particular on the role of pioglitazone, for this condition. PubMedGoogle Scholar
- 6.••Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31. The best ultrasound-based screening study assessing the prevalence of NAFLD and NASH. PubMedGoogle Scholar
- 7.•Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837–45. The first study that carefully matched Hispanic and Caucasian patients for adiposity by dual X-ray absorptiometry in order to carefully examine the role of ethnicity without this confounding factor. PubMedGoogle Scholar
- 10.••Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, Hecht J, Cusi K. Relationship between disease severity, hyperinsulinemia and impaired insulin clearance in patients with nonalcoholic steatohepatitis (NASH). Hepatology. 2014. doi: 10.1002/hep.26988. Novel study that examines the etiology of hyperinsulinemia in NAFLD and the role of steatohepatitis and fibrosis in the developemnt of impaired insulin clearance at the level of the liver and peripheral tissues.
- 13.Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Phys India. 2009;57:205–10.Google Scholar
- 18.Bril F, Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus: Current controversies and future directions. Diabetes Care. 2014; (in press).Google Scholar
- 22.Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Hardies J, Tio F, et al. Impact of glucose tolerance status on insulin sensitivity and disease severity in patients with NAFLD. Diabetes. 2012;61 suppl 1:A1761.Google Scholar
- 23.Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Amer J Gastroenterol. 2013;108:1861–8.Google Scholar
- 34.••Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–6. Excellent prospective on the impact of risk factors such as obesity and T2DM in the progression of NASH. PubMedGoogle Scholar
- 41.Iozzo P, Pratipanawatr T, Pijl H, Vogt C, Kumar V, Pipek R, et al. Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. Am J Physiol. 2001;280:E712–9.Google Scholar
- 42.Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol. 2010;52:727–36.PubMedCentralPubMedGoogle Scholar
- 43.••Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Mendez-Lucas A, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res. 2012;53:1080–92. Novel animal study on the role of mitochondrial dysfunction in the pathogenesis of hepatic steatosis. PubMedCentralPubMedGoogle Scholar
- 48.••Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14:804–10. Landmark study in humans offering strong evidence on the role of mitochondrial dysfunction, TCA cycle and gluconeogenesis in the pathogenesis of hepatic steatosis. PubMedCentralPubMedGoogle Scholar
- 52.Kashyap S, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, et al. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol. 2004;287:E537–46.Google Scholar
- 55.Bril F, Lomonaco R, Portillo-Sanchez P, Orsak B, Maximos M, Finch J, Webb A, Cusi K. Does Nonalcoholic Fatty Liver Disease (NAFLD) Develop in Insulin Sensitive Patients? Diabetes. 2014 (accepted abstract 1804-P).Google Scholar
- 70.Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60:832–8.Google Scholar
- 72.Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45:750–7.PubMedGoogle Scholar
- 73.•Bril F, Lomonaco R, Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clin Lipidol. 2012;7:471–81. Comprehensive review on the role of dyslipidemia and impact of lipid-lowering agents in NAFLD and NASH. Google Scholar
- 75.Debosch BJ, Chen Z, Saben JL, Finck BN, Moley KH. Glucose Transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J Biol Chem. 2014. doi: 10.1074/JBC.M113.527002.
- 78.Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, Ha V, Di Buono M, Jenkins AL, Leiter LA et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr. 2014. doi: 10.1038/ejcn.2014.8.
- 87.••Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with NAFLD (The RAED2 randomized trial). Hepatology. 2013;58:1287–95. Well-designed controlled study comparing aerobic vs. resistance exercise for the treatment of NAFLD. PubMedGoogle Scholar
- 89.Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Ther Adv Gastroenterol. 2013;6:249–59.Google Scholar
- 96.Cusi K, Orsak B, Lomonaco R, Bril F, Ortiz-Lopez C, Hecht J, Webb A, Tio F, Darland CM, Hardies J. Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH. Hepatology. 2013; 58(Supplement 1):Abstract #82.Google Scholar
- 97.Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diabetes Rep. 2013;13:329–41.Google Scholar
- 103.Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51:1584–92.PubMedCentralPubMedGoogle Scholar
- 104.Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int Off J Int Study Liver. 2006;26:1015–7.Google Scholar
- 105.Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Amer J Gastroenterol. 2010;105:2707–9.Google Scholar
- 106.Mendoza CA, Mathew M, Chen J, Diaz N, Kaminski-Grant R, Darland C, et al. Exenatide promotes weight loss and improves insulin secretion, subclinical inflammation, and hepatic steatosis when replaced for premeal insulin in T2DM patients. Diabetes. 2009;58:A135.Google Scholar
- 108.Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. doi: 10.1136/bmjopen-2013-003995.
- 111.Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.PubMedCentralPubMedGoogle Scholar
- 113.Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J, Ploton M, Mazuy C, Caron S, Tailleux A et al. The glucose sensing O-GlcNacylation pathway regulates the nuclear bile acid receptor FXR. Hepatology. 2013. doi: 10.1002/hep.26710.
- 114.•Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–82. e571. This study examines the effect of this novel agent on insulin sensitivity and other metabolic variables in patients with NAFLD. PubMedGoogle Scholar
- 115.Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Amer J Physiol. 2007;292:E829–35.Google Scholar